TFX
Teleflex Incorporated
$129.68
-0.58% 2026-10-19
Health CareS&P 600
TFXSPY
1W
+3.2%
1M
+4.1%
3M
-3.0%
6M
-1.2%
YTD
+7.1%
1Y
+2.3%
Grades vs sector
Momentum33rd pct in sectorC-
Momentum
33rd pct in sector
12-1 return: +1.6%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth88th pct in sectorA-
Growth
88th pct in sector
Revenue growth (YoY): +28.9%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value55th pct in sectorC+
Value
55th pct in sector
Forward E/P: 8.4% · EBITDA/EV: 5.0%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability13th pct in sectorD-
Profitability
13th pct in sector
Profit margin: -45.8% · Return on equity: -0.7%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$5.5B
P/E (trailing)–
P/E (forward)11.8
52-week range100.18 – 145.00
Revenue growth (YoY, latest qtr)+28.9%
Dividend yield1.04%
Analyst consensusBuy (11)
Mean price target$154.00 (+19%)
Valuation & fundamentals
Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
▲Forward P/E vs sector11.8x vs median 17.6x
▼Piotroski F-score3/9
•Altman Z2.1 (grey)
▼Net debt / EBITDA11.5x
▲Analyst target+19% (11 analysts)
Discounted cash flow
Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Not enough data to run a reverse DCF.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.83 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
sector median 29.9×
–Forward P/E
cheaper
sector median 17.6× · 23rd pct
11.8×cheaper
EV / EBITDA
pricier
sector median 15.8× · 88th pct
33.4×pricier
Price / sales
cheaper
sector median 3.1× · 39th pct
2.4×cheaper
Price / book
cheaper
sector median 3.5× · 20th pct
1.9×cheaper
FCF yield
sector median 4.1%
–Forward EPS $10.94 vs trailing $-8.48. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
54.9%
Operating margin
2.0%
FCF margin
–
Net margin
-45.8%
Return on equity
-35.5%
Return on invested capital
0.6%
Net debt / EBITDA
11.5×
Current ratio
2.6×
Interest cover
0.4×
Cash conversion (OCF/NI)
–
Piotroski F-score 3/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✗ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 2.1 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$154
+19%
Analysts
11
Buy
Range
$138–$170
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $2.0B | $-905.6M | – |
| 2024 | $1.7B | $69.7M | – |
| 2023 | $1.7B | $356.3M | – |
| 2022 | $2.8B | $363.1M | – |
| 2021 | $2.8B | $485.4M | – |
| 2020 | $2.5B | $335.3M | – |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -10.6%.
Earnings
Next report: 2026-10-29 · before open · EPS est 1.89
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | 1.28 | 1.76 | +37.4% |
| 2026-05-07 | 1.21 | 1.39 | +14.5% |
| 2026-02-26 | 3.75 | 1.93 | -48.5% |
| 2025-11-06 | 3.38 | 3.67 | +8.6% |
| 2025-07-31 | 3.37 | 3.73 | +10.8% |
| 2025-05-01 | 2.88 | 2.91 | +0.9% |
| 2025-02-27 | 3.88 | 3.89 | +0.4% |
| 2024-10-31 | 3.39 | 3.49 | +2.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $570.3M | +28.9% |
| 2026-03-31 | $548.3M | – |
| 2025-12-31 | $-401.9M | – |
| 2025-09-30 | $913.0M | – |
| 2025-06-30 | $442.5M | – |
Analyst actions
Truist Securities
PT $142
2026-10-14 · main
Hold → HoldPT $142
B of A Securities
PT $158
2026-09-28 · up
Neutral → BuyPT $158
Needham
PT $170
2026-08-25 · main
Buy → BuyPT $170
UBS
PT $158
2026-08-11 · main
Neutral → NeutralPT $158
Truist Securities
PT $150
2026-08-10 · main
Hold → HoldPT $150
Piper Sandler
PT $169
2026-08-07 · reit
Overweight → OverweightPT $169
Recent dividends
2026-08-14: $0.340 · 2026-05-22: $0.340 · 2026-03-06: $0.340 · 2025-11-14: $0.340 · 2025-08-15: $0.340 · 2025-05-20: $0.340 · 2025-03-07: $0.340 · 2024-11-15: $0.340
Insider trades
None
–
None · None
SELL–
News
Stats refreshed 2026-10-19 17:46:50 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.